Equity Profile

ZBH

Zimmer Biomet Holdings, Inc.

Health CareHealth Care Equipment$19.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Zimmer Biomet Holdings, Inc. is a healthcare company that specializes in orthopedic products and surgical solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding how well the company is expanding its market presence and meeting customer demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZBH Q2-2026 Earnings Preview

Context

Company Snapshot

Zimmer Biomet Holdings, Inc. is a healthcare company that specializes in orthopedic products and surgical solutions. With a market cap of $19 billion, it plays a crucial role in the health care equipment sector, particularly as demand for medical devices continues to grow due to an aging population and increasing health care needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+2.87%

Avg Stock Reaction

-3.79%

Last Quarter Recap

In Q1-2026, Zimmer Biomet reported an EPS of $2.09, exceeding expectations by 12.55%. However, the stock dropped 10.57% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on innovation in orthopedic solutions.
Commitment to improving operational efficiency.
Plans to expand market reach in emerging regions.

Expectations

Wall Street Expectations

Overall, analysts are cautiously optimistic about Zimmer Biomet's upcoming earnings, given its history of beating EPS estimates. However, there are concerns about revenue growth and market conditions.

Bull Case

If Zimmer Biomet can demonstrate strong revenue growth and maintain or improve its operating margins, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations on revenue or shows signs of declining margins, it could trigger a negative response from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to expand and meet market demand, which investors will closely monitor.

How is the company managing its operating margins amidst rising costs?

Operating margins will indicate how well Zimmer Biomet is controlling expenses, which is vital for sustaining profitability in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zimmer Biomet's potential for revenue growth due to its recent innovations and market expansion efforts.

Supporting Evidence

The company has a strong history of beating EPS estimates, which could translate to better-than-expected revenue.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not be reflected in consensus estimates.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to grow revenues and manage costs effectively in a challenging economic environment.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.66%

Historical Avg

±7.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±13.7% while ZBH has averaged ±7.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.8%

Calls (12K)P/C Ratio: 0.43Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zimmer Biomet beats expectations, history suggests the stock could rise by an average of 5.15%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see limited movement as investors reassess their expectations.

Miss

Should the company miss expectations, history indicates a potential drop of around 5.71%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth expectations for the upcoming quarter.
2Updates on new product launches and their market reception.
3Insights into cost management strategies and their impact on margins.
4Any commentary on competitive pressures in the orthopedic market.
5Management's outlook on future market conditions and growth opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Zimmer Biomet Holdings, Inc. is a healthcare company that specializes in orthopedic products and surgical solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding how well the company is expanding its market presence and meeting customer demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZBH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+2.87%

Avg Stock Reaction

-3.79%

Last Quarter Recap

In Q1-2026, Zimmer Biomet reported an EPS of $2.09, exceeding expectations by 12.55%. However, the stock dropped 10.57% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on innovation in orthopedic solutions.
Commitment to improving operational efficiency.
Plans to expand market reach in emerging regions.

Expectations

Wall Street Expectations

Bull Case

If Zimmer Biomet can demonstrate strong revenue growth and maintain or improve its operating margins, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations on revenue or shows signs of declining margins, it could trigger a negative response from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to expand and meet market demand, which investors will closely monitor.

How is the company managing its operating margins amidst rising costs?

Operating margins will indicate how well Zimmer Biomet is controlling expenses, which is vital for sustaining profitability in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zimmer Biomet's potential for revenue growth due to its recent innovations and market expansion efforts.

Supporting Evidence

The company has a strong history of beating EPS estimates, which could translate to better-than-expected revenue.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not be reflected in consensus estimates.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to grow revenues and manage costs effectively in a challenging economic environment.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.66%

Historical Avg

±7.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±13.7% while ZBH has averaged ±7.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.8%

Calls (12K)P/C Ratio: 0.43Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zimmer Biomet beats expectations, history suggests the stock could rise by an average of 5.15%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see limited movement as investors reassess their expectations.

Miss

Should the company miss expectations, history indicates a potential drop of around 5.71%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth expectations for the upcoming quarter.
2Updates on new product launches and their market reception.
3Insights into cost management strategies and their impact on margins.
4Any commentary on competitive pressures in the orthopedic market.
5Management's outlook on future market conditions and growth opportunities.